Damora Therapeutics, Inc. DMRA
22.08 USD +0.48 (+2.22%)
At closeNov 3, 2026, 4:00 PM EST
22.08 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
21.70 Day range 22.77
4.95 52-week range 38.33
- YTD
- -4.04%
- 1 year
- +229.55%
- Market cap
- 1.36B
- EPS (ttm)
- -0.25
- Shares out
- 61.74M
- Forward P/E
- -10.16
- YTD return
- -4.04%
- 1-year return
- +229.55%
- Volume
- 473.17K
- Avg volume
- 529.17K
- Open
- 21.76
- Previous close
- 21.60
- Day's range
- 21.70 – 22.77
- 52-week range
- 4.95 – 38.33
- Beta
- 1.51
- Analysts
- Strong Buy
- Price target
- 46.89 (+112.4%)
- Earnings date
- Nov 5, 2026
1m +0.32 (+1.47%)
Key statistics
- Enterprise value
- 922.97M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 3.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.98M
- Total cash
- 540.52M
- Total debt
- 0
- Return on equity
- -99.74%
- Short % of float
- 9.74%
- 50-day average
- 23.35
- 200-day average
- 25.64
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 46.89 +112.4% upside
Now 22.08
- Target (low)
- 40.00
- Target (mean)
- 46.89
- Target (high)
- 60.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.435.
Financials — quick view
DMRA Revenue — quarterly 0
DMRA Net income — quarterly -31.17M
DMRA EPS — quarterly -0.39
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.48251 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.41395 | -0.39 | +0.02 | +5.79% |
| May 12, 2026 | Mar 31, 2026 | -0.21 | -0.62 | -0.41 | -195.24% |
| Mar 18, 2026 | Dec 31, 2025 | -0.14 | -3.24 | -3.10 | -2,216.35% |
| Nov 6, 2025 | Sep 30, 2025 | -0.09681 | -2.36 | -2.26 | -2,337.76% |
| Aug 5, 2025 | Jun 30, 2025 | — | -2.60 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 2026 | Wedbush | reit | Outperform | Outperform |
| Sep 25, 2026 | Guggenheim | main | Buy | Buy |
| Jul 30, 2026 | Wedbush | main | Outperform | Outperform |
| Jul 27, 2026 | Jefferies | init | — | Buy |
| Jul 21, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 12, 2026 | Wedbush | reit | Outperform | Outperform |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- damoratx.com
News
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday 
Wedbush Reiterates Outperform on Damora Therapeutics, Maintains $40 Price Target 
Guggenheim Maintains Buy on Damora Therapeutics, Raises Price Target to $60 
Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate - Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Study Of DMR-001 To Treat Patients With Mutcalr-Driven Essential Thrombocythemia And Myelofibrosis
Wedbush Maintains Outperform on Damora Therapeutics, Raises Price Target to $40 
This Warner Bros Discovery Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday 
This Damora Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Jefferies Initiates Coverage On Damora Therapeutics with Buy Rating, Announces Price Target of $50
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Your note
Sign in to keep a note on DMRA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUNO JULIANNE | Director | Conversion of Exercise of derivative security | Feb 8, 2026 | 137,032 |
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 8, 2026 | 0 |
| FIRMANI LORI | Chief Financial Officer | Sale | Jan 1, 2026 | 931 |
| HEWES LEMUEL BECKER | Officer | Stock Award(Grant) | Jan 4, 2026 | 264,629 |
| JARRETT A JENNIFER | Chief Executive Officer | Purchase | Sep 24, 2026 | 512,500 |
| SATTARZADEH SHERWIN | Chief Operating Officer | Stock Award(Grant) | Jan 4, 2026 | 190,376 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Associates Inc | 0.08% | 48,743 | 1.08M | Jun 29, 2026 |
| Profund Advisors LLC | 0.02% | 11,573 | 255.53K | Sep 29, 2026 |
| STRS Ohio | 0.02% | 12,800 | 282.62K | Sep 29, 2026 |
| Harbour Investments, Inc. | 0.00% | 40 | 883 | Jun 29, 2026 |
| Gamma Investing LLC | 0.00% | 91 | 2.01K | Sep 29, 2026 |
| Farther Finance Advisors, Llc | 0.00% | 40 | 883 | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.97% | 1,835,051 | 40.52M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.99% | 1,227,145 | 27.10M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.35% | 834,040 | 18.42M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.17% | 723,719 | 15.98M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.95% | 584,529 | 12.91M | Aug 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 0.88% | 540,246 | 11.93M | Aug 30, 2026 |